Predictors of HFNC Failure in Patients With AHRF Using Echocardiography Parameters

Acute Hypoxemic Respiratory Failure Clinical Trial

— AHRF-ECHO  

Official title:

Predictors of High-Flow Nasal Cannula Failure (HFNC) in Patients With Acute Hypoxemic Respiratory Failure (AHRF) Using Echocardiography Parameters

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06096363
• Other study ID #: UW 23-086-01
• Status: Recruiting
• Start date: April 28, 2023
• Est. completion date: September 1, 2024

Study information

• Verified date: October 2023
• Source: Queen Mary Hospital, Hong Kong
• Contact: Wincy Ng, MRCP
• Phone: 22553111
• Email: wincyngwingsze[@]gmail.com
• Is FDA regulated: No
• Study type: Observational [Patient Registry]

Clinical Trial Summary

Right ventricular dysfunction (RVD) and right ventricular-pulmonary arterial (RV-PA) uncoupling detected by transthoracic echocardiography (TTE) in acute respiratory distress syndrome (ARDS) are associated with poor survival. Early detection of RVD and RV-PA uncoupling in patients with acute hypoxemic respiratory failure (AHRF) may be indicative of worsening and decompensating pulmonary condition which may require escalation of respiratory support. The use of TTE parameters in predicting high-flow nasal cannula (HFNC) failure has not been previously studied. The objective of this study is to identify predictors of HFNC failure by TTE and to compare its performance with the well-established ROX index.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 30
• Est. completion date: September 1, 2024
• Est. primary completion date: July 1, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• Age ? 18; AND

• Acute hypoxemic respiratory failure (AHRF), defined by respiratory rate of greater than 25 breaths per minute and a ratio of the PaO2 to the fraction of inspired oxygen (PaO2 / FiO2) of less than 300, and use of accessory muscles of respiration or paradoxical abdominal motion; AND

• Required ventilatory support with high-flow nasal cannula (HFNC)

Exclusion Criteria:

• Patients suffering from hypercapnic respiratory failure; OR

• AHRF secondary to conditions that are indicated for non-invasive ventilation (NIV) (e.g. acute exacerbation of COPD, cardiogenic pulmonary edema); OR

• Use of NIV or invasive mechanical ventilation (IMV) prior to HFNC initiation; OR

• Patients with imminent need for endotracheal intubation and invasive mechanical ventilation (IMV); OR

• Patients with known or suspected diaphragm paralysis; OR

• Pregnancy; OR

• Patients with abdominal compartment syndrome; OR

• Use of HFNC for more than 12 hours prior to ICU admission; OR

• Patients with suboptimal echocardiographic image quality for data processing; OR

Related Conditions & MeSH terms

• Acute Hypoxemic Respiratory Failure
• Respiratory Insufficiency

Intervention

Diagnostic Test:
• Transthoracic Echocardiography
Transthoracic Echocardiography to look for evidence of right ventricular (RV) dysfunction and right ventricular-pulmonary arterial (RV-PA) uncoupling.

Locations

Country	Name	City	State
Hong Kong	Queen Mary Hospital	Hong Kong

Sponsors (1)

Lead Sponsor	Collaborator
Queen Mary Hospital, Hong Kong

Country where clinical trial is conducted

Hong Kong, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	High-flow nasal cannula (HFNC) therapeutic failure	Predictive value of transthoracic echocardiography (TTE) in detecting High-flow nasal cannula (HFNC) therapeutic failure in patients with acute hypoxemic respiratory failure (AHRF).	From the start of recruitment into study (i.e. start of HFNC use), till the date of study endpoint (i.e., step up to non-invasive ventilation, intubation, death on HFNC, or weaned off HFNC, whichever came first), assessed up to 4 weeks.